Announcements Trials

Browse Landscape

Status

No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Leukemia, Biphenotypic, Acute 6 Leukemia 5 Recurrence 1 Colorectal Neoplasms 1 Acute Myeloid Leukemia With KMT2A Rearrangement 1

Interventions

Cyclophosphamide 51 fludarabine 37 Dexamethasone 35 venetoclax 30 pembrolizumab 25 Rituximab 20 pomalidomide 18 Lenalidomide 17 Gemcitabine 17 fludarabine phosphate 15 Etoposide 14 Cytarabine 13 daratumumab 12 carfilzomib 11 Temozolomide 11 Injections 10 Calcium Dobesilate 10 glofitamab 9 Nivolumab 9 Cisplatin 9 Bortezomib 9 Azacitidine 9 selinexor 8 Vincristine 8 Immunotherapy, Adoptive 8 obinutuzumab 7 cemiplimab 7 Drug Therapy 7 Carboplatin 7 zanubrutinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × revumenib × 1 year × Clear all

NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available

Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡